Dogwood (DWTX) Therapeutics announces the dosing of the first patient in its Phase 2b clinical trial, referred to as HALT-CINP, evaluating Halneuron for the treatment of neuropathic pain associated with prior chemotherapy treatment.
Don’t Miss TipRanks’ Half Year Sale
- Take advantage of TipRanks Premium for 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
- Make smarter investment decisions with TipRanks' Smart Investor Picks, delivered to your inbox every week.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on DWTX: